ASC39 / Ascletis - LARVOL DELTA

ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity (ADA 2026) - "ASC39 is an eloralintide-like selective and potent oral small molecule amylin receptor agonist development candidate with a novel scaffold. Both ASC39 and eloralintide demonstrated a strong selectivity towards hAMY1R over hCTR and a comparable preclinical efficacy in DIO rats. Oral ASC39's attractive pharmacological profile supports its advancement into human clinical trials, alone and in combination to offer a novel, convenient, accessible and differentiated obesity therapeutic option."

Late-breaking abstract • Metabolic Disorders • Obesity

Potent Oral Amylin Receptor Agonist: ASC39 (PRNewswire) - "In a diet-induced obesity (DIO) rat model, ASC39 was administered orally once daily at doses of 0.2 mg/kg, 1 mg/kg, and 5 mg/kg. A clear dose-dependent reduction in body weight was observed. At Day 11, animals receiving 5 mg/kg ASC39 achieved a 9.9% reduction in body weight from baseline, compared with a 2.8% reduction in the placebo group (p < 0.01)...In a separate head-to-head DIO rat study, ASC39 (5 mg/kg, oral, once daily) was compared with eloralintide (3 nmol/kg, subcutaneous injection, once every three days). Both agents induced body weight reductions beginning on Day 2 following treatment initiation. By Day 7, body weight had decreased by 6.0% (p < 0.0001) and 5.0% (p < 0.0001) from baseline in the ASC39 group and eloralintide group, respectively, while body weight increased by 0.6% in the placebo group."

Preclinical • Obesity

Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions (The Manila Times) - "The presentations include a late breaking poster presentation on the preclinical data of ASC39, an eloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity."

Preclinical • Obesity

Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models (HKEXnews) - "In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide....In a head-to-head diet-induced obese (DIO) rat study vs. eloralintide, efficacy of ASC39 oral dosing was comparable to that of eloralintide, demonstrating significant placebo adjusted weight loss of 6.6% and 5.6% for ASC39 and eloralintide, respectively. Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC39 oral tablets is expected in the third quarter of 2026."

IND • Preclinical • Obesity